lactic acid has been researched along with Dermatoses in 39 studies
Lactic Acid: A normal intermediate in the fermentation (oxidation, metabolism) of sugar. The concentrated form is used internally to prevent gastrointestinal fermentation. (From Stedman, 26th ed)
2-hydroxypropanoic acid : A 2-hydroxy monocarboxylic acid that is propanoic acid in which one of the alpha-hydrogens is replaced by a hydroxy group.
| Excerpt | Relevance | Reference |
|---|---|---|
| "In order to investigate the efficacy of anthralin ( Anthraderm ) in the treatment of warts a randomized controlled trial was carried out in 72 patients." | 5.05 | Wart treatment with anthralin. ( Brandrup, F; Flindt-Hansen, H; Tikjøb, G, 1984) |
| " OBJECTIVE To review the use of injectable PLLA, specifically regarding optimal injection technique that can reduce adverse events (AEs) and enhance out comes." | 2.44 | Minimizing adverse events associated with poly-L-lactic acid injection. ( Narins, RS, 2008) |
| "Vancomycin was linked to the injectable hydrogel via the reversible Schiff's base reaction, and VEGF were encapsulated into PLGA microspheres." | 1.48 | Tunable sequential drug delivery system based on chitosan/hyaluronic acid hydrogels and PLGA microspheres for management of non-healing infected wounds. ( Chen, G; Huang, J; Li, Z; Liu, Y; Ren, J; Wang, G; Wu, X, 2018) |
| "Polylactic acid (PLA) is an agent that is injected with the aim of enhancing the host's own collagen deposition." | 1.34 | Adverse reactions to polylactic acid injections in the periorbital area. ( Apikian, M; Goodman, GJ; Roberts, S, 2007) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 8 (20.51) | 18.7374 |
| 1990's | 6 (15.38) | 18.2507 |
| 2000's | 9 (23.08) | 29.6817 |
| 2010's | 11 (28.21) | 24.3611 |
| 2020's | 5 (12.82) | 2.80 |
| Authors | Studies |
|---|---|
| Corazza, M | 1 |
| Guarneri, F | 1 |
| Montesi, L | 1 |
| Toni, G | 1 |
| Donelli, I | 1 |
| Borghi, A | 1 |
| Zhou, LD | 1 |
| Lu, YN | 1 |
| Liu, Q | 1 |
| Shi, XM | 1 |
| Tian, J | 1 |
| Liu, M | 1 |
| Yu, W | 1 |
| Fang, Y | 1 |
| Zhou, H | 1 |
| Liang, Y | 1 |
| Huang, C | 1 |
| Liu, H | 1 |
| Zhao, G | 1 |
| Jiang, WC | 1 |
| Zhang, H | 1 |
| Xu, Y | 2 |
| Jiang, C | 1 |
| Liu, W | 1 |
| Tan, Y | 1 |
| Zheng, Y | 1 |
| Liang, H | 1 |
| Li, Z | 2 |
| Tang, M | 1 |
| Song, L | 1 |
| Huang, J | 1 |
| Ren, J | 1 |
| Chen, G | 1 |
| Liu, Y | 1 |
| Wang, G | 1 |
| Wu, X | 1 |
| Lee, KC | 1 |
| Wambier, CG | 1 |
| Soon, SL | 1 |
| Sterling, JB | 1 |
| Landau, M | 1 |
| Rullan, P | 1 |
| Brody, HJ | 1 |
| Daines, SM | 1 |
| Williams, EF | 1 |
| Salam, A | 1 |
| Dadzie, OE | 1 |
| Galadari, H | 1 |
| Chiang, WL | 1 |
| Lin, TT | 1 |
| Sureshbabu, R | 1 |
| Chia, WT | 1 |
| Hsiao, HC | 1 |
| Liu, HY | 1 |
| Yang, CM | 1 |
| Sung, HW | 1 |
| Zhu, X | 1 |
| Zeng, X | 1 |
| Zhang, X | 1 |
| Cao, W | 1 |
| Wang, Y | 1 |
| Chen, H | 1 |
| Wang, T | 1 |
| Tsai, HI | 1 |
| Zhang, R | 1 |
| Chang, D | 1 |
| He, S | 1 |
| Mei, L | 1 |
| Shi, X | 1 |
| Ehnis-Pérez, A | 1 |
| Torres-Álvarez, B | 1 |
| Cortés-García, D | 1 |
| Hernández-Blanco, D | 1 |
| Fuentes-Ahumada, C | 1 |
| Castanedo-Cázares, JP | 1 |
| Narins, RS | 1 |
| Cohen, JL | 1 |
| Rancan, F | 1 |
| Papakostas, D | 1 |
| Hadam, S | 1 |
| Hackbarth, S | 1 |
| Delair, T | 1 |
| Primard, C | 1 |
| Verrier, B | 1 |
| Sterry, W | 1 |
| Blume-Peytavi, U | 1 |
| Vogt, A | 1 |
| WOHNLICH, H | 1 |
| Davis, JA | 1 |
| Visscher, MO | 1 |
| Wickett, RR | 1 |
| Hoath, SB | 1 |
| STERN, EC | 1 |
| Sadick, NS | 1 |
| Coutanceau, C | 1 |
| Sibaud, V | 1 |
| Merial-Kieny, C | 1 |
| Shirali, AC | 1 |
| Look, M | 1 |
| Du, W | 1 |
| Kassis, E | 1 |
| Stout-Delgado, HW | 1 |
| Fahmy, TM | 1 |
| Goldstein, DR | 1 |
| Mohr, B | 1 |
| Fernandez, MP | 1 |
| Krejci-Manwaring, J | 1 |
| LEBENGLIK, M | 1 |
| KAMINSKY, A | 1 |
| Godfried, MH | 1 |
| Boer, K | 1 |
| Beuger, S | 1 |
| Scherpbier, HJ | 1 |
| Kuijpers, TW | 1 |
| Hodzic-Avdagic, N | 1 |
| Stege, H | 1 |
| Hilton, S | 1 |
| Sarbia, M | 1 |
| Ruzicka, T | 1 |
| Bruch-Gerharz, D | 1 |
| Apikian, M | 1 |
| Roberts, S | 1 |
| Goodman, GJ | 1 |
| COCA, AF | 1 |
| Pons-Guiraud, A | 1 |
| Rongioletti, F | 1 |
| Flindt-Hansen, H | 1 |
| Tikjøb, G | 1 |
| Brandrup, F | 1 |
| Kanno, T | 1 |
| Maekawa, M | 1 |
| Berg, M | 1 |
| Lonne-Rahm, SB | 1 |
| Fischer, T | 1 |
| Coverly, J | 1 |
| Peters, L | 1 |
| Whittle, E | 1 |
| Basketter, DA | 1 |
| Burmeister, JE | 1 |
| Fox, LK | 1 |
| Hillers, JK | 1 |
| Hancock, DD | 1 |
| Muizzuddin, N | 1 |
| Marenus, KD | 1 |
| Maes, DH | 1 |
| Takken, W | 1 |
| Lachapelle, JM | 1 |
| Leroy, B | 1 |
| Van Scott, EJ | 1 |
| Yu, RJ | 1 |
| Baden, HP | 1 |
| Mayron, R | 1 |
| Grimwood, RE | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| 6 Month Double-Blind Randomized Placebo-Controlled Trial to Evaluate the Safety and Efficacy of Small Particle Hyaluronic Acid to Treat Acne Scars Located on the Cheeks and Forehead[NCT02955381] | 26 participants (Actual) | Interventional | 2017-03-28 | Terminated (stopped due to Liquidation of Research Department) | |||
| A Single Center Clinical Study to Evaluate the Tolerance of an Acne Treatment in Sensitive Skin Subjects With Mild to Moderate Acne Vulgaris[NCT03128723] | 45 participants (Actual) | Interventional | 2017-04-30 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Cutaneous Tolerance Scores: Burning/Stinging (assessing skin burning/stinging), from Baseline to Day 14. Scale range is 0-3 where 0 = no burning/stinging, 1 = mild burning/stinging, 2 = moderate burning/stinging, and 3 = severe burning/stinging. (NCT03128723)
Timeframe: Baseline to Day 14
| Intervention | Units on a scale (Mean) |
|---|---|
| Acne Mask | 0.02 |
Cutaneous Tolerance Scores: Burning/Stinging (assessing skin burning/stinging), from Baseline to Day 28. Scale range is 0-3 where 0 = no burning/stinging, 1 = mild burning/stinging, 2 = moderate burning/stinging, and 3 = severe burning/stinging. (NCT03128723)
Timeframe: Baseline to Day 28
| Intervention | Units on a scale (Mean) |
|---|---|
| Acne Mask | 0.00 |
Cutaneous Tolerance Scores: Dryness/Scaling (assessing skin dryness), from Baseline to Day 14. Scale range is 0-3, where 0 = no dryness, 1 = mild dryness, 2 = moderate dryness, and 3 = severe dryness. (NCT03128723)
Timeframe: Baseline to Day 14
| Intervention | Units on a scale (Mean) |
|---|---|
| Acne Mask | -0.11 |
Cutaneous Tolerance Scores: Dryness/Scaling (assessing skin dryness), from Baseline to Day 28. Scale range is 0-3, where 0 = no dryness, 1 = mild dryness, 2 = moderate dryness, and 3 = severe dryness. (NCT03128723)
Timeframe: Baseline to Day 28
| Intervention | Units on a scale (Mean) |
|---|---|
| Acne Mask | -0.14 |
Cutaneous Tolerance Scores: Edema (assessing skin edema/swelling), from Baseline to Day 14. Scale range is 0-3 where 0 = no edema, 1 = mild edema, 2 = moderate edema, and 3 = severe edema. (NCT03128723)
Timeframe: Baseline to Day 14
| Intervention | Units on a scale (Mean) |
|---|---|
| Acne Mask | 0.00 |
Cutaneous Tolerance Scores: Edema (assessing skin edema/swelling), from Baseline to Day 28. Scale range is 0-3 where 0 = no edema, 1 = mild edema, 2 = moderate edema, and 3 = severe edema. (NCT03128723)
Timeframe: Baseline to Day 28
| Intervention | Units on a scale (Mean) |
|---|---|
| Acne Mask | 0.00 |
Cutaneous Tolerance Scores: Erythema (assessing skin redness), from Baseline to Day 14. Scale range is 0-3 where 0 = no redness, 1 = mild redness, 2 = moderate redness, and 3 = severe redness. (NCT03128723)
Timeframe: Baseline to Day 14
| Intervention | Units on a scale (Mean) |
|---|---|
| Acne Mask | -0.09 |
Cutaneous Tolerance Scores: Erythema (assessing skin redness), from Baseline to Day 28. Scale range is 0-3 where 0 = no redness, 1 = mild redness, 2 = moderate redness, and 3 = severe redness. (NCT03128723)
Timeframe: Baseline to Day 28
| Intervention | Units on a scale (Mean) |
|---|---|
| Acne Mask | -0.07 |
Cutaneous Tolerance Scores: Itching (assessing skin itching), from Baseline to Day 14. Scale range is 0-3 where 0 = no itching, 1 = mild itching, 2 = moderate itching, and 3 = severe itching. (NCT03128723)
Timeframe: Baseline to Day 14
| Intervention | Units on a scale (Mean) |
|---|---|
| Acne Mask | 0.04 |
Cutaneous Tolerance Scores: Itching (assessing skin itching), from Baseline to Day 28. Scale range is 0-3 where 0 = no itching, 1 = mild itching, 2 = moderate itching, and 3 = severe itching. (NCT03128723)
Timeframe: Baseline to Day 28
| Intervention | Units on a scale (Mean) |
|---|---|
| Acne Mask | 0.00 |
Cutaneous Tolerance Scores: Tightness/Dry Feeling (assessing skin tightness/dry feeling), from Baseline to Day 14. Scale range is 0-3 where 0 = no tightness/dry feeling, 1 = mild tightness/dry feeling, 2 = moderate tightness/dry feeling, and 3 = severe tightness/dry feeling. (NCT03128723)
Timeframe: Baseline to Day 14
| Intervention | Units on a scale (Mean) |
|---|---|
| Acne Mask | -0.02 |
Cutaneous Tolerance Scores: Tightness/Dry Feeling (assessing skin tightness/dry feeling), from Baseline to Day 28. Scale range is 0-3 where 0 = no tightness/dry feeling, 1 = mild tightness/dry feeling, 2 = moderate tightness/dry feeling, and 3 = severe tightness/dry feeling. (NCT03128723)
Timeframe: Baseline to Day 28
| Intervention | Units on a scale (Mean) |
|---|---|
| Acne Mask | -0.05 |
4 reviews available for lactic acid and Dermatoses
| Article | Year |
|---|---|
Basic chemical peeling: Superficial and medium-depth peels.
Topics: Caustics; Chemexfoliation; Drug Combinations; Ethanol; Glycolates; Humans; Keratolytic Agents; Lacti | 2019 |
Chemical peeling in ethnic skin: an update.
Topics: Caustics; Chemexfoliation; Combined Modality Therapy; Humans; Keratolytic Agents; Lactic Acid; Medic | 2013 |
Minimizing adverse events associated with poly-L-lactic acid injection.
Topics: Cellulose; Cosmetic Techniques; Drug Compounding; Face; Female; Granuloma, Foreign-Body; HIV-Associa | 2008 |
Understanding, avoiding, and managing dermal filler complications.
Topics: Animals; Biocompatible Materials; Cattle; Collagen; Cosmetic Techniques; Durapatite; Female; Foreign | 2008 |
2 trials available for lactic acid and Dermatoses
| Article | Year |
|---|---|
Efficacy and safety of a new topical keratolytic treatment for localized hyperkeratosis in adults.
Topics: Administration, Topical; Adult; Double-Blind Method; Drug Delivery Systems; Drug Tolerance; Europe; | 2010 |
Wart treatment with anthralin.
Topics: Adolescent; Adult; Anthracenes; Anthralin; Child; Clinical Trials as Topic; Copper; Drug Combination | 1984 |
33 other studies available for lactic acid and Dermatoses
| Article | Year |
|---|---|
Proposal of a self-assessment questionnaire for the diagnosis of sensitive skin.
Topics: Adult; Cross-Sectional Studies; Humans; Lactic Acid; Reproducibility of Results; Self-Assessment; Sk | 2022 |
Modulation of TRPV1 function by Citrus reticulata (tangerine) fruit extract for the treatment of sensitive skin.
Topics: Capsaicin; Citrus; Fruit; Humans; Lactic Acid; Pain; Plant Extracts; Skin Diseases; TRPV Cation Chan | 2023 |
Pyruvate and lactate based hydrogel film inhibits UV radiation-induced skin inflammation and oxidative stress.
Topics: Dihydroxyphenylalanine; Humans; Hydrogels; Inflammation; Lactic Acid; Oxidative Stress; Pyruvic Acid | 2023 |
Cutaneous vessel features of sensitive skin and its underlying functions.
Topics: Adult; Capsaicin; Case-Control Studies; China; Female; Humans; Lactic Acid; Male; Microvascular Dens | 2020 |
Skin microbiome in sensitive skin: The decrease of Staphylococcus epidermidis seems to be related to female lactic acid sting test sensitive skin.
Topics: Cosmetics; DNA, Bacterial; Female; Humans; Hyperesthesia; Lactic Acid; Microbiota; RNA, Ribosomal, 1 | 2020 |
Tunable sequential drug delivery system based on chitosan/hyaluronic acid hydrogels and PLGA microspheres for management of non-healing infected wounds.
Topics: Animals; Bacteria; Biocompatible Materials; Cell Proliferation; Chitosan; Cytokines; Drug Carriers; | 2018 |
Complications associated with injectable soft-tissue fillers: a 5-year retrospective review.
Topics: Adult; Aged; Biocompatible Materials; Cosmetic Techniques; Durapatite; Female; Follow-Up Studies; Hu | 2013 |
A rapid drug release system with a NIR light-activated molecular switch for dual-modality photothermal/antibiotic treatments of subcutaneous abscesses.
Topics: Abscess; Animals; Anti-Bacterial Agents; Drug Delivery Systems; Hot Temperature; Infrared Rays; Inje | 2015 |
The effects of quercetin-loaded PLGA-TPGS nanoparticles on ultraviolet B-induced skin damages in vivo.
Topics: Animals; Antioxidants; Cell Line; Drug Carriers; Female; Humans; Keratinocytes; Lactic Acid; Mice; N | 2016 |
Relationship between transient receptor potential vanilloid-1 expression and the intensity of sensitive skin symptoms.
Topics: Adult; Female; Gene Expression; Humans; Hyperesthesia; Lactic Acid; Male; Middle Aged; RNA, Messenge | 2016 |
Investigation of polylactic acid (PLA) nanoparticles as drug delivery systems for local dermatotherapy.
Topics: Dermatologic Agents; Drug Delivery Systems; Humans; Lactic Acid; Nanoparticles; Polyesters; Polymers | 2009 |
Mix with lactic acid lactate buffer to treat inflammatory dermatoses.
Topics: Humans; Lactates; Lactic Acid; Skin Diseases | 1946 |
Role of TNF-α polymorphism -308 in neurosensory irritation.
Topics: Adult; DNA; Dose-Response Relationship, Drug; Female; Genotype; Humans; Lactic Acid; Male; Middle Ag | 2011 |
Topical application of lactic acid in the treatment and prevention of certain disorders of the skin.
Topics: Humans; Lactic Acid; Skin; Skin Diseases | 1946 |
Nanoparticle delivery of mycophenolic acid upregulates PD-L1 on dendritic cells to prolong murine allograft survival.
Topics: Animals; Antibiotics, Antineoplastic; B7-H1 Antigen; Cells, Cultured; Combined Modality Therapy; Den | 2011 |
Eruptive keratoacanthomas after Jessners and trichloroacetic acid peel for actinic keratosis.
Topics: Chemexfoliation; Drug Combinations; Ethanol; Humans; Keratoacanthoma; Keratosis, Actinic; Lactic Aci | 2013 |
[Dextro-rotarory lactic acid and racemic lactic acid in the treatment of psoriasis and parakeratotic dermatosis].
Topics: Dermatology; Lactates; Lactic Acid; Psoriasis; Skin Diseases | 1961 |
A neonate with macrosomia, cardiomyopathy and hepatomegaly born to an HIV-infected mother.
Topics: Adipose Tissue; Antiretroviral Therapy, Highly Active; Arginine; Asphyxia; Brain; Cardiomegaly; Card | 2005 |
[Granuloma development after wrinkle injection with polylactate].
Topics: Cosmetic Techniques; Female; Granuloma; Humans; Injections, Subcutaneous; Lactic Acid; Middle Aged; | 2005 |
Adverse reactions to polylactic acid injections in the periorbital area.
Topics: Cellulose; Cosmetic Techniques; Dermatologic Agents; Face; Female; Granuloma, Foreign-Body; Humans; | 2007 |
The factor L. casei in the therapy of certain dermatological syndromes; Folic acid (transl.).
Topics: Bacteria; Lactic Acid; Lactobacillus; Skin Diseases | 1948 |
[Classification of the fillers available in France].
Topics: Absorbable Implants; Biocompatible Materials; Cosmetic Techniques; France; Granuloma; Humans; Hyalur | 2008 |
[Granulomatous reactions from aesthetic dermal micro-implants].
Topics: Absorbable Implants; Acrylates; Biocompatible Materials; Collagen; Cosmetic Techniques; Dimethylpoly | 2008 |
Lactate dehydrogenase M-subunit deficiencies: clinical features, metabolic background, and genetic heterogeneities.
Topics: Adolescent; Adult; Base Sequence; DNA; Exercise; Female; Glyceraldehyde-3-Phosphate Dehydrogenases; | 1995 |
Patients with visual display unit-related facial symptoms are stingers.
Topics: Adult; Computer Terminals; Dermatitis, Contact; Female; Humans; Irritants; Lactic Acid; Male; Occupa | 1998 |
Susceptibility to skin stinging, non-immunologic contact urticaria and acute skin irritation; is there a relationship?
Topics: Acrolein; Acute Disease; Administration, Topical; Adult; Anti-Inflammatory Agents; Antimutagenic Age | 1998 |
Effects of premilking and postmilking teat disinfectants on teat skin condition.
Topics: Animals; Body Water; Cattle; Cattle Diseases; Chlorides; Disinfectants; Epidermis; Female; Iodine; L | 1998 |
Factors defining sensitive skin and its treatment.
Topics: Adult; Balsams; Cosmetics; Dermatitis, Contact; Dermatologic Agents; Epidermis; Erythema; Exanthema; | 1998 |
Malaria mosquitoes favor the human skin and not expired air.
Topics: Animals; Anopheles; Humans; Insect Bites and Stings; Lactic Acid; Malaria; Odorants; Skin; Skin Dise | 2000 |
Allergic contact dermatitis to colophony included in the formulation of flexible collodion BP, the vehicle of a salicylic and lactic acid wart paint.
Topics: Adult; Collodion; Dermatitis, Contact; Female; Humans; Lactates; Lactic Acid; Patch Tests; Pharmaceu | 1990 |
Alpha hydroxy acids: procedures for use in clinical practice.
Topics: Acne Vulgaris; Administration, Topical; Glycolates; Humans; Ichthyosis; Keratosis; Lactates; Lactic | 1989 |
Management of fingertip cracking with Epilyt.
Topics: Butylated Hydroxytoluene; Drug Combinations; Fingers; Humans; Lactates; Lactic Acid; Propylene Glyco | 1989 |
Familial occurrence of eruptive vellus hair cysts.
Topics: Administration, Cutaneous; Adolescent; Age Factors; Biopsy; Child; Child, Preschool; Diagnosis, Diff | 1988 |